Summary
Guardant Health, Inc. has executed privately negotiated exchange agreements to issue $600 million in aggregate principal amount of new 1.25% Convertible Senior Notes due 2031 (New Notes) in exchange for approximately $659.3 million of its outstanding 0% Convertible Senior Notes due 2027 (2027 Notes). This transaction effectively extends the maturity of a significant portion of its convertible debt and lowers the immediate cash interest expense. The exchange is expected to close on or about February 14, 2025. Following the transaction, approximately $490.7 million of the 2027 Notes will remain outstanding.
Key Highlights
- 1Debt Exchange: Guardant Health is exchanging $659.3 million of its 0% Convertible Senior Notes due 2027 for $600 million of new 1.25% Convertible Senior Notes due 2031.
- 2Reduced Interest Expense: The new notes carry a 1.25% annual interest rate, a significant reduction compared to the 0% rate on the exchanged notes, though this represents a new cash interest obligation.
- 3Extended Maturity: The new notes mature in February 2031, extending the maturity profile of a portion of the company's convertible debt from 2027.
- 4Share Repurchase Program: The company intends to repurchase approximately $45 million of its common stock, and the exchange agent plans to purchase approximately $35 million, from certain participants in the transaction.
- 5Conversion Terms: The new notes have an initial conversion rate of 16.0716 shares per $1,000 principal, implying an initial conversion price of approximately $62.22 per share, representing a premium of about 35% to the stock price on February 6, 2025.
- 6Redemption and Fundamental Change Provisions: The new notes are redeemable by the company under specific conditions after February 2028 and can be repurchased by noteholders in the event of a "Fundamental Change".
- 7Unregistered Offering: The new notes are issued under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act, based on private negotiations with certain holders.
Frequently Asked Questions
The primary financial impact is the extension of debt maturity for a significant portion of convertible notes and the introduction of a cash interest payment. While the company is exchanging a larger principal amount of old notes for a smaller principal amount of new notes, it is now obligated to pay 1.25% cash interest semi-annually on the new notes, which were previously 0% interest bearing.
The company and the exchange agent intend to repurchase a total of approximately $80 million of Guardant Health's common stock from participants in the exchange. This action could potentially provide some support to the stock price around the transaction date, but it also represents a use of cash.
The new convertible notes are convertible into Guardant Health's common stock at an initial conversion price of approximately $62.22 per share. If the stock price rises above this level and noteholders convert their notes, it will result in the issuance of new shares, leading to potential dilution for existing shareholders. The maximum number of shares issuable initially is approximately 13 million, based on the conversion rate.
The new notes mature on February 15, 2031. Noteholders can convert their notes before November 15, 2030, only upon the occurrence of certain specified events. From November 15, 2030, until the close of business on the second trading day before maturity, noteholders can convert at their election.